Molecular Partners AG is indeed a publicly traded biopharmaceutical company, listed on the SIX Swiss Exchange under the ticker symbol MOLN. By offering its shares on public financial markets, the company enables institutional investors, funds, and retail participants to acquire equity ownership. This public status provides the enterprise with vital capital to fund its extensive clinical research, laboratory operations, and the continuous development of its proprietary DARPin protein therapeutic pipelines targeting oncology, immunology, and infectious diseases.